AXIIF (Alexium International Group) Total Stockholders Equity: $-2.39 Mil (As of Dec. 2025)


What is Alexium International Group Total Stockholders Equity?

Alexium International Group AXIIF Total Stockholders Equity is $-2.39 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Alexium International Group's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-2.39 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Alexium International Group's Book Value per Share for the quarter that ended in Dec. 2025 was $-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Alexium International Group's Debt-to-Equity for the quarter that ended in Dec. 2025 was -1.68.


Alexium International Group  (OTCPK:AXIIF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Alexium International Group's Book Value per Share for the quarter that ended in Dec. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Alexium International Group's Debt-to-Equity for the quarter that ended in Dec. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexium International Group Total Stockholders Equity Related Terms


Alexium International Group Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Alexium International Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alexium International Group Total Stockholders Equity Chart

Alexium International Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.18 1.58 -0.98 3.30 -0.40

Alexium International Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.08 3.30 1.73 -0.40 -2.39
What does a Total Stockholders Equity of $-2.39 Mil mean?
Alexium International Group (AXIIF) has a Total Stockholders Equity of $-2.39 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alexium International Group and its competitors.
Is Alexium International Group's Total Stockholders Equity too high?
Alexium International Group's current Total Stockholders Equity is $-2.39 Mil.
How does Alexium International Group's Total Stockholders Equity compare to LIN and SHW?
Alexium International Group's Total Stockholders Equity of $-2.39 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Chemicals company?
A good Total Stockholders Equity depends on the Chemicals industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alexium International Group and its competitors. Alexium International Group's current Total Stockholders Equity is $-2.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alexium International Group stock overvalued right now?
Alexium International Group (AXIIF) has a current Total Stockholders Equity of $-2.39 Mil. The current Total Stockholders Equity is $-2.39 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Alexium International Group (AXIIF), the current Total Stockholders Equity is $-2.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alexium International Group Business Description

Other Exchanges E7T:GermanyAJX:Australia
Address 350 West Phillips Road, Greer, SC, USA, 29650
Alexium International Group Ltd is engaged in the development of specialty chemicals. Its only operating segment is the development and commercialization of its proprietary flame retardant (FR) and phase change material (PCM) chemistries, cooling products for bedding, and selling its specialized chemistry to customers. Geographically, it derives a majority of its revenue from the United States and also has a presence in Australia. The company's product solutions include Alexicool, Alexiflam NF, Eclipsys, Alexiflam, and Alexiguard.